Cases & Deals

  • Home
  • Practices
  • VelaVigo announces out-licensing deal with Ollin of first-in-class bispecific antibody

Share

VelaVigo announces out-licensing deal with Ollin of first-in-class bispecific antibody

April 2025

Client(s) VelaVigo (Hong Kong) Limited

Jones Day assisted VelaVigo with an intellectual property diligence of VBS-102, a first-in-class bispecific antibody, in connection with its out-licensing to Ollin Biosciences, Inc.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.